KALA
KALA BIO, Inc.
Key Financials
Revenue
$0
NaN%
Operating Income
$-39161000
↑ 4.4%
Net Income
$-26980000
↑ 29.9%
Total Liabilities
$2.5M
↓ 94.2%
Total Assets
$9.5M
↓ 82.9%
Cash & Equivalents
$7.6M
↓ 85.2%
EPS (Diluted)
$-3.31
↑ 67.4%
Shareholders' Equity
$7.0M
↓ 43.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-K | 4/15/2026 | View on SEC |
| NT 10-K | 3/31/2026 | View on SEC |
| D | 3/17/2026 | View on SEC |
| 144 | 3/17/2026 | View on SEC |
| 144 | 3/12/2026 | View on SEC |
| 144 | 3/12/2026 | View on SEC |
| 8-K | 3/4/2026 | View on SEC |
| 8-K | 2/20/2026 | View on SEC |
| EFFECT | 2/17/2026 | View on SEC |
| 424B3 | 2/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | KALA |
| Company Name | KALA BIO, Inc. |
| CIK | 1479419 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 781-996-5252 |